Megakaryon CEO Miwa aims to start mass in vitro production of blood by 2020. At present, the company can only make a few units of blood every two weeks. In Japan alone, annual demand totals 800,000 units. Megakaryon is working with Japanese drugmakers and manufacturers of materials to create a mass-production system.
In vitro blood will be a boon to both wealthy countries and developing ones, Miwa said. It can reduce the risk of infection in places where a proper blood donation and screening system has yet to be established and the risky underground trade in blood is widespread.
SOURCE - Nikkei